Enanta Pharmaceuticals (ENTA) EPS (Weighted Average and Diluted) (2012 - 2026)
Enanta Pharmaceuticals posted quarterly EPS (Weighted Average and Diluted) of -$0.45 for Q1 2026, up 57.55% year-on-year from -$0.29 in Q1 2025, and down 7.14% on a QoQ basis from -$0.42 in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.45 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 57.55% year-over-year to -$0.45; the trailing twelve-month figure through Mar 2026 stood at -$2.6 (up 42.73% YoY), and the FY2025 full-year result was -$3.84, up 29.93% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.45, down from -$0.42 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.42 in Q4 2025 and bottomed at -$1.86 in Q2 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.33 (2023), against an average of -$1.23.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) plunged 49.54%; it then surged 60.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.39 in 2022, then declined by 13.67% to -$1.58 in 2023, then soared by 33.54% to -$1.05 in 2024, then soared by 60.0% to -$0.42 in 2025, then decreased by 7.14% to -$0.45 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.45 (Q1 2026), -$0.42 (Q4 2025), and -$0.88 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | -0.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.45 |
| Dec 31, 2025 | -0.42 |
| Sep 30, 2025 | -0.88 |
| Jun 30, 2025 | -0.85 |
| Mar 31, 2025 | -1.06 |
| Dec 31, 2024 | -1.05 |
| Sep 30, 2024 | -1.36 |
| Jun 30, 2024 | -1.07 |
| Mar 31, 2024 | -1.47 |
| Dec 31, 2023 | -1.58 |
| Sep 30, 2023 | -1.33 |
| Jun 30, 2023 | -1.86 |
| Mar 31, 2023 | -1.79 |
| Dec 31, 2022 | -1.39 |
| Sep 30, 2022 | -1.27 |
| Jun 30, 2022 | -1.53 |
| Mar 31, 2022 | -1.63 |
| Dec 31, 2021 | -1.48 |
| Sep 30, 2021 | -1.22 |
| Jun 30, 2021 | -1.19 |
| Mar 31, 2021 | -1.09 |
| Dec 31, 2020 | -0.41 |
| Sep 30, 2020 | -1.46 |
| Jun 30, 2020 | -0.71 |
| Mar 31, 2020 | -0.30 |
| Dec 31, 2019 | 0.65 |
| Sep 30, 2019 | 0.44 |
| Jun 30, 2019 | 0.33 |
| Mar 31, 2019 | 0.20 |
| Dec 31, 2018 | 1.25 |
| Sep 30, 2018 | 1.30 |
| Jun 30, 2018 | 0.97 |
| Mar 31, 2018 | 0.61 |
| Dec 31, 2017 | 0.59 |
| Sep 30, 2017 | 1.86 |
| Jun 30, 2017 | -0.44 |
| Mar 31, 2017 | -0.28 |
| Dec 31, 2016 | -0.26 |
| Sep 30, 2016 | -0.09 |
| Jun 30, 2016 | -0.06 |
| Mar 31, 2016 | -0.09 |
| Dec 31, 2015 | 1.37 |
| Sep 30, 2015 | 0.29 |
| Jun 30, 2015 | 0.13 |
| Mar 31, 2015 | 1.49 |
| Dec 31, 2014 | 2.18 |
| Sep 30, 2014 | -0.27 |
| Jun 30, 2014 | 2.61 |
| Mar 31, 2014 | -0.28 |
| Dec 31, 2013 | -0.30 |
| Sep 30, 2013 | -0.25 |
| Jun 30, 2013 | -0.23 |
| Mar 31, 2013 | -2.28 |
| Dec 31, 2012 | 1.45 |
| Sep 30, 2012 | -4.78 |
| Jun 30, 2012 | -4.31 |
| Mar 31, 2012 | 2.17 |